9 Evidence-Based Facts About HRT Safety for Women Who Have Migraines With Aura
Being told 'you can't have HRT because you get migraines with aura' without any further conversation is one of the most frustrating things women in this community describe. It's a statement that leaves them stuck — with symptoms, with confusion, and with the feeling that their particular situation just doesn't matter. The evidence deserves more than a blanket no.
Learn more about Rose →Migraine with aura independently raises stroke risk — and that's the real starting point
Migraine with aura is classified as an independent risk factor for ischaemic stroke, roughly doubling baseline risk in women of reproductive age. This isn't about HRT at all — it's a baseline consideration that should inform every conversation about hormones, contraception, and cardiovascular health. Understanding this risk is the foundation for everything else on this list, not a reason to stop reading.
Oral oestrogen increases clotting risk in a way that transdermal oestrogen does not
When oestrogen is taken orally, it passes through the liver first — a process called first-pass metabolism — which increases production of clotting factors and raises the risk of venous thromboembolism. Transdermal oestrogen (patches, gels, sprays) bypasses the liver entirely and does not produce the same prothrombotic effect. For women with migraine with aura, this distinction is clinically important and is supported by multiple observational studies.
Transdermal oestrogen appears to be the safer route for women with migraine with aura
Current guidance from bodies including the British Menopause Society indicates that transdermal oestrogen is the preferred route for women with migraine with aura, specifically because it avoids the liver-mediated clotting effects of oral preparations. The evidence base here is observational rather than from large randomised trials, but the physiological rationale is well established. This is one of the clearest examples where route of administration changes the entire risk conversation.
Fluctuating oestrogen levels can trigger migraines — stable dosing matters
Many women with migraine with aura find that hormonal fluctuation, rather than a sustained hormone level, is what triggers attacks — a pattern well recognised in menstrual migraine, where the drop in oestrogen before a period is the trigger. During perimenopause, these fluctuations become erratic and pronounced, which can actually worsen migraine frequency before it improves. Maintaining stable oestrogen levels through consistent transdermal delivery may reduce this fluctuation-driven triggering effect.
The type of progestogen used in HRT also matters for migraine and vascular risk
Synthetic progestogens (progestins) used in some combined HRT preparations have been associated with negative vascular effects and may influence migraine frequency in sensitive individuals. Micronised progesterone — the bioidentical form — has a more neutral vascular profile and is generally better tolerated by women whose migraines are sensitive to hormonal change. For women with migraine with aura, micronised progesterone is widely considered the preferable choice within combined HRT regimens.
HRT is not the same as the combined oral contraceptive pill — the risks are different
The combined oral contraceptive pill is contraindicated in women with migraine with aura due to its significantly elevated stroke risk, and this is well evidenced. HRT uses much lower doses of oestrogen than the pill, delivered differently, and the risk profile is not equivalent — yet many women (and some clinicians) conflate the two. Treating these as interchangeable categories leads to blanket refusals of HRT that aren't supported by the evidence.
Absolute stroke risk for most perimenopausal women remains low, even with migraine with aura
While migraine with aura doubles the relative risk of ischaemic stroke, the absolute baseline risk for women under 55 is very small — meaning doubling a small number still produces a small number. Additional modifiable risk factors — smoking, hypertension, obesity, and inactivity — have a far larger impact on absolute risk than HRT in transdermal form. Putting the numbers in context is essential to meaningful shared decision-making.
Some women with migraine with aura find that HRT reduces attack frequency after menopause
Once natural hormonal fluctuations cease after menopause, some women with migraine with aura report a reduction in attack frequency — and stable-dose transdermal HRT can help maintain that hormonal steadiness rather than disrupting it. This isn't a universal experience, but it illustrates that HRT isn't automatically a migraine aggravator for this group. Individual response varies considerably, and tracking migraine patterns before and after starting HRT is clinically useful.
Individual risk stratification — not a blanket rule — should guide the decision
No single recommendation applies to every woman with migraine with aura: personal and family history of stroke, cardiovascular risk factors, blood pressure, smoking status, and the severity of menopausal symptoms all need to be weighed together. The goal is an informed, individualised conversation with a clinician experienced in menopause medicine — not a reflexive no based on an outdated or oversimplified risk framework. Women who are told HRT is simply off the table deserve a more complete explanation, and ideally a second opinion from a menopause specialist.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.